Journals / European Journal of Breast Health / 2020 / Cilt: 16 - Sayı: 1

A Comparison of the Clinicopathological Features, Metastasis Sites and Survival Outcomes of Invasive Lobular, Invasive Ductal and Mixed Invasive Ductal and Lobular Breast Carcinoma

Pages
22–31
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Distant metastasis-free survival (DMFS) rate was 66.2% in ILCpatients, 66.7% in IDC patients, 57.1% in IDLC patients; in multivariate Cox analysis, histological type had no prognostic significance (p=0.392).Conclusion: Although these results suggest that IDLC may have a worse prognosis than IDC and ILC, in multivariate analysis LRFS and DMFS werenot significantly different among the histological type groups.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: We compared the breast cancer patients with invasive lobular carcinoma (ILC), invasive ductal carcinoma (IDC) and mixed invasive ductaland lobular carcinoma (IDLC) in terms of clinicopathological and treatment features, metastatic patterns and long-term survival.Materials and Methods: In a 10 years patient cohort, 3412 patients with unilateral breast carcinoma were enrolled in the study.
📊
Key Findings & Data:Tumors were classifiedhistologically according to criteria described by World Health Organization classification.Results: The highest rate of T3 tumors were found in IDLC patients, the lowest in IDC patients, and the difference between groups was significant onlyin comparison of IDC vs IDLC.
💡
Conclusion & Impact:Distant metastasis-free survival (DMFS) rate was 66.2% in ILCpatients, 66.7% in IDC patients, 57.1% in IDLC patients; in multivariate Cox analysis, histological type had no prognostic significance (p=0.392).Conclusion: Although these results suggest that IDLC may have a worse prognosis than IDC and ILC, in multivariate analysis LRFS and DMFS werenot significantly different among the histological type groups.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: We compared the breast cancer patients with invasive lobular carcinoma (ILC), invasive ductal carcinoma (IDC) and mixed invasive ductaland lobular carcinoma (IDLC) in terms of clinicopathological and treatment features, metastatic patterns and long-term survival.Materials and Methods: In a 10 years patient cohort, 3412 patients with unilateral breast carcinoma were enrolled in the study. Tumors were classifiedhistologically according to criteria described by World Health Organization classification.Results: The highest rate of T3 tumors were found in IDLC patients, the lowest in IDC patients, and the difference between groups was significant onlyin comparison of IDC vs IDLC. Axillary positivity rate was highest in IDLC, lowest in ILC; differences were significant in comparisons of IDLC vs ILCand IDLC vs IDC. There was no significant difference between the patient groups in terms of surgical treatment, mastectomy and breast conservingsurgery. Rate of bone metastasis was highest in IDLC, lowest in IDC, with significant difference between IDLC and IDC. Locoregional recurrence-freesurvival (LRFS) rate was 90.9% in ILC patients, 92.5% in IDC patients, 92.9% in IDLC patients, with no significant difference between the groups;in multivariate Cox analysis, histological type had no prognostic significance (p=0.599). Distant metastasis-free survival (DMFS) rate was 66.2% in ILCpatients, 66.7% in IDC patients, 57.1% in IDLC patients; in multivariate Cox analysis, histological type had no prognostic significance (p=0.392).Conclusion: Although these results suggest that IDLC may have a worse prognosis than IDC and ILC, in multivariate analysis LRFS and DMFS werenot significantly different among the histological type groups.

🔖

Cite This Article

DURAKER, N., HOT, S., AKAN, A., NAYIR, P. Ö. (2022). A Comparison of the Clinicopathological Features, Metastasis Sites and Survival Outcomes of Invasive Lobular, Invasive Ductal and Mixed Invasive Ductal and Lobular Breast Carcinoma. European Journal of Breast Health, Cilt: 16 - Sayı: 1, 22–31. https://ajindex.com/articles/510770

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Pestalozzi BC, Zahrieh D, Mallon E, Gusterson BA, Price KN, Gelber RD, Holmberg SB, Lindtner J, Snyder R, Thürlimann B, Murray E, Viale G, Castiglione-Gertsch M, Coates AS, Goldhirsch A. Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials. J Clin Oncol 2008; 26: 3006-3014. (PMID: 18458044
  2. Corben AD. Pathology of invasive breast disease. Surg Clin North Am 2013; 93: 363-392. (PMID: 23464691
  3. Mamtani A, King TA. Lobular breast cancer: different disease, different algorithms? Surg Oncol Clin N Am 2018; 27: 81-94. (PMID: 29132567
  4. Chen C-L, Weiss NS, Newcomb P, Barlow W, White E. Hormone replacement therapy in relation to breast cancer. JAMA 2002; 287: 734-741. (PMID: 11851540
  5. Li CI, Anderson BO, Daling JR, Moe RE. Trends in incidence rates of invasive lobular and ductal breast carcinoma. JAMA 2003; 289: 1421-1424. (PMID: 12636465
  6. Biglia N, Mariani L, Sgro L, Mininanni P, Moggio G, Sismondi P. Increased incidence of lobular breast cancer in women treated with hormone replacement therapy: implications for diagnosis, surgical and medical treatment. Endocr Relat Cancer 2007; 14: 549-567. (PMID: 17914088
  7. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC Cancer Staging Handbook, 7th edn. New York: Springer-Verlag, 2010
  8. Silverstein MJ, Lewinsky BS, Waisman JR, Gierson ED, Colburn WJ, Senofsky GM, Gamagami P. Infiltrating lobular carcinoma: is it different from infiltrating duct carcinoma? Cancer 1994; 73: 1673-1677. (PMID: 8156495
  9. Mersin H, Yıldırım E, Gülben K, Berberoğlu U. Is invasive lobular carcinoma different from invasive ductal carcinoma? Eur J Surg Oncol 2003; 29: 390-395. (PMID: 12711296
  10. Arpino G, Bardou VJ, Clark GM, Elledge RM. Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. Breast Cancer Res 2004; 6: R149-R156. (PMID: 15084238
  11. Wasif N, Maggard MA, Ko CY, Giuliano AE. Invasive lobular vs. ductal breast cancer: a stage-matched comparison of outcomes. Ann Surg Oncol 2010; 17: 1862-1869. (PMID: 20162457
  12. Kwast AB, Groothuis-Oudshoorn KC, Grandjean I, Ho VK, Voogd AC, Menke-Pluymers MB, van der Sangen MJ, Tjan-Heijnen VC, Kiemeney LA, Siesling S. Histological type is not an independent prognostic factor for the risk pattern of breast cancer recurrences. Breast Cancer Res Treat 2012; 135: 271-280. (PMID: 22810087
  13. Brouckaert O, Laenen A